"Also of interest are personally tailored vaccine strategies, such as the one that made a splash earlier this month at AIDS Vaccine 2009, the annual meeting of the Global HIV Vaccine Enterprise, in Paris. AGS-004, being developed by North Carolina–based Argos, customizes immune system cells from each individual, using HIV fragments known as messenger RNA, to maximize an HIV-positive person’s immune response to the virus. To do this, dendritic cells are removed from the body and combined with mRNA taken from the same individual’s HIV. The data presented at the Paris conference showed that the vaccine, when given just before an ARV treatment interruption, kept viral loads at least 1 log—more than an 80 percent reduction—below pre-ARV therapy levels in 13 of 16 patients. Full story...
"A large proportion of HIV-positive men have low bone mineral density, Australian researchers report in the December 1st edition of the Journal of Infectious Diseases.
"Given the association between depressive symptomatology and poor rates of HIV viral suppression, screening and appropriate interventions for depressive symptoms are warranted in the HIV outpatient setting to improve outcomes.
"Needle exchange is AIDS prevention that works. While no one wants to have to put on a condom, every drug user prefers injecting with a clean needle.
"Results of US research 'challenge the notion that nevirapine is uniquely associated with hepatotoxicity during pregnancy.
"A French study of a group of people with HIV aged over 60 has found that over a four-year period, one in seven of the group died – but not a single death was attributable to an AIDS-defining illness.
"Antiretroviral (ARV) therapy is now recommended for certain people living with HIV with CD4 counts between 350 and 500 cells, according to new HIV treatment guidelines released this week by the European AIDS Clinical Society (EACS).
"A new study adds to the evidence that vitamin D deficiency is common in people living with HIV. The new data, from an Italian study reported last week at the 12th European AIDS Conference in Cologne, Germany, and summarized by the National AIDS Treatment Advocacy Project (NATAP), underscore the potential importance of testing for and treating low vitamin D levels to thwart the increased risk of bone deterioration and immune system dysfunction in those infected with the virus.
"An entire session at the 12th European AIDS Conference was devoted to trials of different ritonavir-boosted protease inhibitors (PI/r) used as the sole drug in an antiretroviral regimen.
"1. Brainstorm ideas and identify specific action steps that address the three National HIV/AIDS Strategy goals to reduce HIV incidence, increase access to care and optimize health outcomes for people living with HIV, and reduce HIV-related health disparities.
"People with higher HIV levels are more likely to have a cluster of symptoms—called metabolic syndrome—associated with cardiovascular disease than people with lower viral loads, according to a study published in the December [2009] issue of the Journal of Acquired Immune Deficiency Syndromes.
Have your say - be the first to comment
Login